Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Differences in Clinical Outcomes between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients

Sung-Yong Kim, Sung-Eun Lee, Junshik Hong, Soo-Mee Bang, Jinny Park, Chul Won Choi, Sung Hwa Bae, Min Kyoung Kim, Seug Yun Yoon

Blood (2023) 142 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2023-177822

Published: 2023

Journal Articles

CDDO Induces Differentiation through PTEN Expression in HL-60 Cells

Jinny Park, Jong-Suk Kim, On-Yu Hong

Blood (2022) 140 (Supplement 1): 11487–11488.

https://doi.org/10.1182/blood-2022-159320

Published: 2022

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Evaluation of Clinical Usefulness of Monocyte Gating Using CD14 and CD64 for Detecting PNH Clone By Flow Cytometry

Woo Jae Kwoun, MD, Jeong-Yeal Ahn, MD, Ja Young Seo, MD, Jae Hoon Lee, MD PhD, Hawk Kim, MD PhD, Jinny Park, MD PhD, Kwai Han Yoo, MD, Sung-Ran Cho, MD, Hye Ryoun Kim, MD

Blood (2018) 132 (Supplement 1): 4947.

https://doi.org/10.1182/blood-2018-99-111468

Published: 2018

Journal Articles

Glutathione Ameliorates Bortezomib (Velcade) -Induced Neuronal Toxicity in N2a and SHSY5Y Cells

Jinny Park, MDPhD, Lalita Subedi, MS, Su Jung Park, MD, Oh kyung Lim, ChanJong Yoo, MD PhD, Jong-Suk Kim, MD PhD, Sun Yeou Kim, PhD

Blood (2018) 132 (Supplement 1): 5863.

https://doi.org/10.1182/blood-2018-99-115711

Published: 2018

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

Blood (2017) 130 (Supplement 1): 4257.

https://doi.org/10.1182/blood.V130.Suppl_1.4257.4257

Published: 2017

Journal Articles

LIGHT (TNFSF14) Increases Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells Via LTβR

Hawk Kim, Sook-Kyoung Heo, PhD, Eui-Kyu Noh, PhD, Gi-Dong Gwon, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD PhD, Jinny Park

Blood (2016) 128 (22): 4546.

https://doi.org/10.1182/blood.V128.22.4546.4546

Published: 2016

Journal Articles

Prognostic Impact of Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome

Blood (2016) 128 (22): 5432.

https://doi.org/10.1182/blood.V128.22.5432.5432

Published: 2016

Journal Articles

PPARγ Agonists Inhibit Adhesion Signal to Endothelial Cells in the Differentiation Induction of HL-60 Acute Promyelocytic Leukemia Cells

Jinny Park, MD PhD, JiWon Yoon, Hong-Nu Yu, MD PhD, Eun-Mi Noh, PhD, On-Yoo Hong, Jong-Suk Kim, MD PhD

Blood (2016) 128 (22): 5131.

https://doi.org/10.1182/blood.V128.22.5131.5131

Published: 2016

Journal Articles

Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Hawk Kim, MD PhD, Je-Hwan Lee, MD PhD, Won-Sik Lee, MD, Inho Kim, Joon Ho Moon, MD, PhD, Chul Won Choi, MD PhD, Ho Sup Lee, MD PhD, Jinny Park, Ho-Jin Shin, Kyoung Ha Kim, MD, Su-Hee Cho, MD PhD, Sung-Yong Kim, MD, Yoo-Jin Kim

Blood (2015) 126 (23): 1687.

https://doi.org/10.1182/blood.V126.23.1687.1687

Published: 2015

Journal Articles

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Blood (2015) 126 (23): 476.

https://doi.org/10.1182/blood.V126.23.476.476

Published: 2015

Journal Articles

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Blood (2015) 126 (23): 4053.

https://doi.org/10.1182/blood.V126.23.4053.4053

Published: 2015

Journal Articles

Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia

Blood (2015) 126 (6): 746–756.

https://doi.org/10.1182/blood-2015-03-636548

Published: 2015

Includes: Supplemental data

Journal Articles

A Prospective Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition of Antithymocyte Globuline for Allogeneic Hematopoietic Cell Transplantation in Patients with Adult Severe Aplastic Anemia; Interim Analysis

Hawk Kim, MD, PhD., Won-Sik Lee, Yeo-Kyeoung Kim, MD PhD, Young-Don Joo, Jinny Park, MD PhD, Chul Won Jung, MD PhD, Jae-Cheol Jo, Jung-Hee Lee, MD PhD, Je-Hwan Lee, MD PhD, Dae-Young Kim, MD, Kyoo-Hyung Lee, MD

Blood (2014) 124 (21): 3890.

https://doi.org/10.1182/blood.V124.21.3890.3890

Published: 2014

Journal Articles

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Blood (2014) 124 (21): 3155.

https://doi.org/10.1182/blood.V124.21.3155.3155

Published: 2014

Journal Articles

Clinical Symptom Or Sign-Directed Surveillance Can Be More Useful In Detecting Relapse Compared To Routine Imaging In Patients With Diffuse Large B-Cell Lymphoma In Remission

Junshik Hong, MD, Ji Hyun Kim, MD, Jinny Park, MD, PhD, Jae Hoon Lee

Blood (2013) 122 (21): 2914.

https://doi.org/10.1182/blood.V122.21.2914.2914

Published: 2013

Journal Articles

Results From The Korean Imatinib Discontinuation Study (KIDS): Updated Data With 14-Month Median Follow Up

Blood (2013) 122 (21): 4003.

https://doi.org/10.1182/blood.V122.21.4003.4003

Published: 2013

NARROW

Differences in Clinical Outcomes between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients

CDDO Induces Differentiation through PTEN Expression in HL-60 Cells

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Evaluation of Clinical Usefulness of Monocyte Gating Using CD14 and CD64 for Detecting PNH Clone By Flow Cytometry

Glutathione Ameliorates Bortezomib (Velcade) -Induced Neuronal Toxicity in N2a and SHSY5Y Cells

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

LIGHT (TNFSF14) Increases Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells Via LTβR

Comparison of Molecular Kinetics after the First and Second Imatinib Discontinuation: Results from the KID Study

Prognostic Impact of Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome

PPARγ Agonists Inhibit Adhesion Signal to Endothelial Cells in the Differentiation Induction of HL-60 Acute Promyelocytic Leukemia Cells

Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia

A Prospective Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition of Antithymocyte Globuline for Allogeneic Hematopoietic Cell Transplantation in Patients with Adult Severe Aplastic Anemia; Interim Analysis

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Clinical Symptom Or Sign-Directed Surveillance Can Be More Useful In Detecting Relapse Compared To Routine Imaging In Patients With Diffuse Large B-Cell Lymphoma In Remission

Results From The Korean Imatinib Discontinuation Study (KIDS): Updated Data With 14-Month Median Follow Up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only